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Cancer is a disease of aging, and aged cancer patients have a poorer prognosis. This may be due to 
accumulated cellular damage, decreases in adaptive immunity, and chronic inflammation. 
However, the effects of the aged microenvironment on tumor progression have been largely 
unexplored. Since dermal fibroblasts can have profound impacts on melanoma progression1–4 we 
examined whether age-related changes in dermal fibroblasts could drive melanoma metastasis and 
response to targeted therapy. We find that aged fibroblasts secrete a Wnt antagonist, sFRP2, which 
activates a multi-step signaling cascade in melanoma cells that results in a decrease in β-catenin 
and MITF, and ultimately the loss of a key redox effector, APE1. Loss of APE1 attenuates the 
response of melanoma cells to ROS-induced DNA damage, rendering them more resistant to 
targeted therapy (vemurafenib). Age-related increases in sFRP2 also augment both angiogenesis 
and metastasis of melanoma cells. These data provide an integrated view of how fibroblasts in the 
aged microenvironment contribute to tumor progression, offering new paradigms for the design of 
therapy for the elderly.
To determine whether the aged microenvironment promotes melanoma progression, 
Yumm1.7 cells, derived from the BrafV600E/Cdkn2a−/−/Pten−/− mouse model of melanoma5, 
were injected into 8-week old mice (young) or 52-week old mice (aged). Tumors grow 
slowly in aged mice (Figure 1a), but are more aggressive, with increased angiogenesis 
(Figure 1b) and lung metastases (Figure 1c, Extended Data 1a). This is consistent with 
observations that melanoma cells switch between proliferative and invasive states, termed 
“phenotype switching”, which depends on changes in Wnt signaling and MITF6,7,8. We have 
shown that phenotype switching to a metastatic, therapy-resistant state is induced by stresses 
such as hypoxia9.
Cross-talk between dermal fibroblasts and transformed melanocytes is critical for melanoma 
invasion1–4 and therapy resistance10. Dermal fibroblasts senesce during aging11, and 
senescent fibroblasts can promote tumor invasion12. To determine whether fibroblasts from 
normally-aged skin could promote tumor progression, we used dermal fibroblasts from 
young (<35) and aged (>55) healthy donors from the Baltimore Longitudinal Study of 
Aging13 (Extended Data Table 1). Proliferation is initially unaffected (Extended Data 1b), 
but aged fibroblasts senesce more rapidly than young fibroblasts (Extended Data 1c). 
Organotypic skin reconstructs were built using two melanoma cell lines (WM35 and 
WM793) and 3 young or 3 aged fibroblast lines, which persisted equally in the skin 
reconstructs as demonstrated by smooth muscle actin staining (Extended Data 1d). 
Melanoma cell invasion was increased, but proliferation was decreased in reconstructs built 
with aged fibroblasts (Figure 1d, e, Extended Data 1e). To assess the effects of secreted 
factors, melanoma cells were exposed to conditioned media from aged or young fibroblasts. 
Aged fibroblast media decreased melanoma cell proliferation (Figure 1f, Extended Data 1f), 
and increased invasion as measured by spheroid and Boyden chamber invasion assays 
(Figure 1g,h Extended Data 1g). These data indicate that secreted factors from fibroblasts 
play critical roles in phenotype switching in melanoma cells.
A key player in phenotype switching is β-catenin, which drives proliferation and inhibits 
invasion of melanoma cells14,15. An inhibitor of β-catenin, sFRP2, was significantly 
increased in the secretome of aged fibroblasts (Figure 2a). In both spheroid and Boyden 
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Chamber assays, media from young fibroblasts treated with recombinant sFRP2 (rsFRP2) 
increased invasion of melanoma cells (Figure 2b, Extended Data 2a) and media from aged 
fibroblasts treated with α-sFRP2 inhibited melanoma cell invasion (Figure 2c, Extended 
Data 2c). In vivo, sFRP2 was increased in sera from aged mice, and these levels could be 
nearly attained in young mice by intravenous injection of rsFRP2 (Figure 2d). Increasing 
serum sFRP2 in young mice increased metastasis of Yumm1.7 to the lung (Figure 2e) and 
increased angiogenesis in subcutaneous tumors (Figure 2f, Extended Data 2c,d). Tumors in 
α-sFRP2 treated mice showed impaired angiogenesis (Figure 2f, Extended Data 2e,f). 
However, α-sFRP2 treated aged mice succumbed to a lethal inflammation (Extended Data 
3), an outcome previously observed in aged immune-competent mice treated with α-PD116.
We next explored the significance of sFRP2 effects on β-catenin expression and activity. 
Treatment of melanoma cells with rsFRP2 inhibited β-catenin expression (Figure 2g), and β-
catenin was decreased in aged human skin (Figure 2h, Extended Data 4a) and in melanoma 
cells treated with aged fibroblast media (Extended Data 4b,c). Yumm1.7 tumors in aged 
mice exhibited decreased β-catenin and increased sFRP2 (Figure 2i), effects reversed by 
treatment of aged mice with α-sFRP2 (Figure 2j). Knockdown of β-catenin in young 
fibroblasts increased their sFRP2 secretion (Figure 2k), which reduced β-catenin and 
increased invasion in melanoma cells (Figure 2l, Extended Data 4d). These data suggest that 
sFRP2 present in the aged microenvironment may contribute to melanoma metastasis 
through suppression of β-catenin in melanoma cells.
The loss of β-catenin permits oxidative stress in hematopoietic stem cells17. We 
hypothesized that the same might occur in melanoma cells, via MITF, which is activated by 
β-catenin18. MITF modulates responses to reactive oxygen species (ROS) by increasing the 
redox effector APE1 (REF-1)19. We predicted that age-induced loss of β-catenin might 
dysregulate the MITF/APE1 redox pathway. Indeed, melanoma cells exposed to aged 
fibroblast media have decreased β-catenin, MITF, and APE1 (Figure 3a). APE1 expression is 
lower in aged human skin (Extended Data 5a), and in Yumm1.7 tumors in aged mice (Figure 
3b). Loss of APE1 reduces cellular responses to ROS. ROS activity is increased in aged 
fibroblasts (Figure 3c), partly due to the fact that aged fibroblasts secrete lower levels of 
superoxide dismutase 3 (SOD3), and peroxiredoxin 6, which scavenge free radicals 
(Extended Data 5b,c). A marker of oxidative stress, 8-oxo-dG, was increased in aged but not 
young skin (Extended Data 5d) and in tumors in aged mice (Figure 3d). Knockdown of 
APE1 in melanoma cells increases ROS activity, especially upon exposure to aged fibroblast 
media (Figure 3e,f, Extended Data 5e). We hypothesized that this loss of ability to respond 
to ROS in an aged environment is partly due to sFRP2 downregulation of APE1. Treating 
young mice with rsFRP2 increases 8-oxo-dG in Yumm1.7 tumors (Figure 3g), while 
depleting sFRP2 in aged mice decreases 8-oxo-dG (Figure 3g). Together, these data indicate 
that sFRP2 increases oxidative stress by inhibiting β-catenin and, ultimately, APE1 in 
melanoma cells (Figure 3h).
Our model indicates that loss of APE1 due to age-induced sFRP2 should render melanoma 
cells sensitive to DNA damage (Extended Data 6a). Accordingly, microarray analysis reveals 
an increased DNA damage response signature in melanoma cells exposed to aged fibroblasts 
(Extended Data 6b,c). The DNA damage markers γH2AX and 53BP1 are increased in 
Kaur et al. Page 3
Nature. Author manuscript; available in PMC 2016 October 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
melanoma cells grown in aged mice (Figure 4a), or exposed to aged fibroblast media (Figure 
4b) or in skin reconstructs built with aged fibroblasts (Extended Data 7a,b). Melanoma cells 
exposed to aged media also had increased levels of DNA damage (Figure 4c, Extended Data 
7c). Pre-treating aged fibroblasts with the anti-oxidant N-acetylcysteine (NAC) decreased 
ROS (Extended Data 7d) and, subsequently, γH2AX in melanoma cells (Figure 4d). 
Conversely, knockdown of the anti-oxidant SOD3 in young fibroblasts increased γH2AX in 
melanoma cells (Figure 4e, Extended Data 7e), suggesting that age-induced DNA damage 
could be reversed by inhibiting ROS activity.
We next queried the contribution of the sFRP2 → APE1 signaling axis to ROS-induced 
DNA damage. Loss of APE1 increases γH2AX (Figure 4f). In melanoma cells, γH2AX also 
increases with treatment of rsFRP2, and decreases in cells where sFRP2 is deleted (Figure 
4g, Extended Data 7f,g). In vivo, 53BP1 increases in Yumm1.7 tumors in young mice 
treated with rsFRP2, and decreases in aged mice treated with α–sFRP2 (Figure 4h). Aged 
melanoma patients (over 55) had significantly higher serum levels of sFRP2 (p=0.0084) than 
young patients (under 40) (Figure 4i). The key players in the pathway outlined in Figure 3h 
were altered in aged melanoma patients: increased sFRP2 (in both fibroblasts and melanoma 
cells), decreased β-catenin, MITF and APE1, and increased 8-oxo-dG and 53BP1 (Figure 4j, 
Extended Data 8). These data confirmed our observations from both human cell line and 
mouse data.
Increases in ROS20,21 and decreases in β-catenin9,22 and MITF23 have been associated with 
increased resistance to BRAF inhibitors. Accordingly, spheroids treated with young medium 
were more sensitive to PLX4720 (vemurafenib) than those exposed to aged medium 
(Extended Data 9a). In vivo, Yumm1.7 tumors in young mice responded to PLX4720 more 
robustly than tumors in aged mice (Figure 5a,b). Melanoma cells first exposed to media 
from young fibroblasts treated with H2O2 (to increase ROS), developed resistance to 
PLX4720 (Figure 5c). However, when we first exposed melanoma cells to media from aged 
fibroblasts pre-treated with NAC, the melanoma cells died, whether treated with NAC alone 
or NAC + PLX4720 (Figure 5d, e). This indicated that vemurafenib-resistant cells in an aged 
microenvironment might be uniquely sensitive to anti-oxidants. This finding is especially 
exciting in light of recent data that indicate that anti-oxidants are effective in treating KRAS 
and BRAF mutant colon cancers24.
Phenotype switching resulting in the loss of β-catenin has also been shown to contribute to 
resistance to vemurafenib9,22. β-catenin expression is elevated in sensitive vs. resistant cell 
lines (Extended Data 9b). Further, patients with clinical response to vemurafenib (over 30% 
tumor reduction as measured by RECIST) had higher levels of β-catenin than those with 
muted response (Figure 5f, g). Yumm1.7 cells are sensitive to PLX4720, and knocking down 
Ctnnb1 in these cells significantly increased their resistance to PLX4720 (Extended Data 
9c). To determine whether sFRP2 alters the response of melanoma cells to vemurafenib, 
rsFRP2 was administered i.v. to tumor-bearing young mice, prior to, and during PLX4720 
exposure. β-catenin was decreased in the skin of sFRP2-treated mice (Extended Data 9d), 
and treated mice rapidly developed resistance to PLX4720 (Figure 5h). Depletion of sFRP2 
in aged mice began to re-sensitize tumors to PLX4720 (Figure 5i, Extended Data 9e), but a 
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firm conclusion cannot be drawn from these data due to the premature death of the mice as 
described earlier.
Since these data suggested that response to BRAF inhibitors may be attenuated in aged 
patients, we compared the age of patients (n=79) at starting treatment to percent tumor 
reduction (RECIST) post-vemurafenib. Using age categories of under 35 and over 55, we 
saw a shift from a 41% (mean) response by RECIST in young patients to 25% (mean) 
response in patients over 55. Numbers of young patients were too low to achieve statistical 
significance. We therefore refocused our efforts on identifying an age cutoff where a 
statistically significant difference could be observed. We observed a striking separation 
(p=0.016) between patients under 65yo and over 65yo (~25.6% reduction in tumor burden in 
aged compared to ~47% in the young, Figure 5j). The continous relationship between 
response and age was highly significant (Spearman’s correlation coefficient of r=0.243, 
p=0.03) (Extended Data 9f). However, in this small sample set, the relationship between 
patient age, sFRP2 and RECIST was not significant. Together, these data suggest that 
sFRP2-induced β-catenin loss not only promotes invasion, but also renders melanoma cells 
more senstive to oxidative stress. New data from Cantley and colleagues show that therapy-
refractory, BRAF mutant cells are uniquely sensitive to anti-oxidants, specifically Vitamin 
C24. Our data support these observations, and suggest that aged patients may uniquely 
benefit from anti-oxidant therapy.
In our experiments, genetically identical cells had a very different outcome in terms of 
metastasis and therapy response when placed in an aged microenvironment. In the skin, 
benign melanocytic lesions (nevi) bear mutational changes that do not result in 
tumorigenesis, until cells accumulate further changes during aging. These changes may be 
genetic, such as loss of p16, but they may also be epigenetic, and age-related epigenetic 
changes also contribute to tumorigenesis25–27. What drives the initiation of these epigenetic 
changes is not well understood, and it is possible that the aged secretome contributes to this 
process. While overall results were consistent among different fibroblasts of similar ages, we 
did observe some phenotypic differences. These may be attributable to factors such as 
tanning, as indeed, the exposure of melanoma cells to UV irradiation not only drives tumor 
promotion28, but also metastasis29. Our data suggest that, as the general population ages, 
new efforts must be made to understand and treat cancer in an age-appropriate manner.
METHODS
Cell Culture
FS5, FS4, FS13, FS14, M93-047, UACC-903 and UACC-1273 cells were maintained in 
RPMI (Invitrogen, Carlsbad, CA), supplemented with 10% FBS, 100 units/ml penicillin and 
streptomycin and 4 mM L-glutamine. WM35, WM793, WM164, WM1799 and 1205LU 
cells were maintained in MCDB153 (Sigma, St Louis, MO)/ L-15 (Cellgro, Manassas, VA) 
(4:1 ratio) supplemented with 2% FBS and 1.6 mM CaCl2 (Tumor growth media). 
WM983b, WM3918 cells were maintained in DMEM (Invitrogen, Carlsbad, CA), 
supplemented with 5% FBS, 100 units/ml penicillin and streptomycin and 4 mM L-
glutamine. YUMM1.7 cells were maintained in DMEM F-12 (Hepes/glutamine) 
supplemented with 10% FBS, 1% NEAA, and 100 units/ml penicillin and streptomycin. 
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Fibroblasts were maintained in DMEM, supplemented with 10% FBS, 100 units/ml 
penicillin and streptomycin and 4 mM L-glutamine. Keratinocytes were maintained in 
keratinocyte SFM supplemented with human recombinant Epidermal Growth Factor 1–53 
(EGF 1–53) and Bovine Pituitary Extract (BPE) (Invitrogen). Cell lines were cultured at 
37°C in 5% CO2 and the medium was replaced as required. Cell stocks were fingerprinted 
using AmpFLSTR® Identifiler® PCR Amplification Kit from Life Technologies TM at The 
Wistar Institute Genomics Facility. Although it is desirable to compare the profile to the 
tissue or patient of origin, our cell lines were established over the course of 40 years, long 
before acquisition of normal control DNA was routinely performed. However, each STR 
profile is compared to our internal database of over 200 melanoma cell lines, as well as 
control lines, such as HeLa and 293T. STR profiles are available upon request. Cell culture 
supernatants were mycoplasma tested using a Lonza MycoAlert assay at the University of 
Pennsylvania Cell Center Services.
Organotypic 3D Skin Reconstructs
Organotypic 3D skin reconstructs were generated as previously described30. In each insert, 
6.4 × 104 fibroblasts were plated on top of the acellular layer (BD #355467 and Falcon 
#353092) and incubated for 45 min at 37°C in a 5% CO2 tissue culture incubator. DMEM 
containing 10% FBS was added to each well of the tissue culture trays and incubated for 4 
days. Reconstructs were then incubated for 1 h at 37°C in HBSS containing 1% dialyzed 
FBS (wash media). Washing media was removed and replaced with reconstruct media I. 
Keratinocytes (4.17 × 105) and melanoma cells (8.3 × 104) were added to the inside of each 
insert. Media was changed every other day until day 18 when reconstructs were harvested, 
fixed in 10% formalin, paraffin embedded, sectioned and stained. Quantification of the 
invasion was performed using ImageJ software (available at http://imagej.nih.gov/ij/; 
developed by Wayne Rasband, National Institutes of Health, Bethesda, MD)
3D Spheroid Assays
Tissue culture-treated 96-well plates were coated with 50 µl 1.5% Difco Agar Noble (Becton 
Dickinson). Melanoma cells were seeded at 5 × 103 cells / well and allowed to form 
spheroids over 72 h. Spheroids were harvested and embedded as previously described using 
collagen type I (GIBCO, #A1048301). For spheroids incubated with fibroblast conditioned 
media, fibroblasts were seeded onto 75 cm2 flasks at 7–9×105/flask depending on growth 
rate. Sixteen hours later, media was replaced and incubated for 72 h. Media from young 
fibroblasts was combined and media from aged fibroblasts was combined. This conditioned 
media was added to the top of the collagen plug containing the spheroids. Quantitation of 
invasive surface area was performed using NIS Elements Advanced Research software.
Live/dead staining
Spheroids were generated and embedded as described above. Spheroids were stained using 
LIVE/DEAD® Viability/Cytotoxicity Kit (L3224, Invitrogen). Briefly, spheroids were 
washed with PBS and stained with calcein AM/Ethidium homodimer-1. The dyes were 
diluted in PBS and 300µl of the solution was added on the spheroid wells for 1 hour at 37°C. 
The spheroids were washed in PBS and imaged using Nikon TE2000 Inverted Microscope. 
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Quantitation of fluorescence intensity was performed using NIS Elements Advanced 
Research software.
Boyden Chamber Invasion assays
Matrigel (BD Biosciences, #354234) was diluted in PBS (1:3000 dilution). 150µl of this 
mixture was pipetted into each insert of the invasion assay plate (Corning, #3422). The plate 
was incubated at 37°C for 2 hours and then dried at room temperature overnight under 
sterile conditions. Melanoma cells were pre-treated for 48 hours in 6 well plates. After 48 
hours, the cells were harvested and 1.5×105 cells were added to each transwell. High 
concentration serum media (RPMI with 20% FCS, Tumor growth media with 10% FCS) was 
added to the outside (bottom) of the well. The plates were incubated at 37°C until cells had 
migrated to the bottom of the well. The migrated cells were fixed in 95% ice-cold methanol 
and stained with crystal violet (0.5%) for 10 minutes. The stain was washed and the wells 
were left to dry. Cells were imaged and quantified using ImageJ software.
Cellular Proliferation assays
In a 24 well plate, 5000 cells in triplicate were plated per day of measurement. Every 2–3 
days, cells were counted using hemocytometer and the total cell number in the well was 
recorded and plotted on Graphpad/Prism.
Immunofluorescence (IF)
Cells were seeded onto glass cover slips at 1–4×104 cells /well, and incubated overnight. 
After treatment, cells were fixed using 95% methanol. Primary antibodies were diluted as 
stated above in blocking buffer and incubated overnight at 4°C. Cells were washed in PBS 
and incubated with the appropriate secondary antibody (1:2000, Invitrogen) for 1 h at room 
temperature. Cells were then washed in PBS and mounted in Prolong Gold anti-fade reagent 
containing DAPI (Invitrogen). Images were captured on a Leica TCS SP5 II scanning laser 
confocal system.
Immunohistochemistry (IHC)
All antibodies are described in the Supplementary Information. Patient samples were 
collected under IRB exemption approval for protocol #EX21205258-1. Paraffin embedded 
sections were rehydrated through a xylene and alcohol series, rinsed in H2O and washed in 
PBS. Antigen retrieval was performed using target retrieval buffer (Vector Labs, 
Burlingame, CA) and steamed for 20 min. Samples were then blocked in a peroxidase 
blocking buffer (Thermo Scientific) for 15 min, followed by Protein block (Thermo 
Scientific) for 5 min, and incubated in appropriate primary antibody diluted in antibody 
diluent (S0809, Dako) at 4°C overnight in a humidified chamber. For mouse samples to be 
incubated with anti-mouse antibody, samples were blocked for 1 hour in Mouse on Mouse 
(M.O.M.™) Blocking Reagent (MKB-2213, Vector Labs). Following washing in PBS, 
samples were incubated in biotinylated anti-rabbit or polyvalent secondary antibody 
(Thermo Scientific) followed by streptavidin-HRP solution at room temperature for 20 min. 
Samples were then washed in PBS and incubated in 3-Amino-9-Ethyl-l-Carboazole (AEC) 
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chromogen and counter stained with Mayers hematoxylin for 1 min, rinsed in cold H2O, and 
mounted in Aquamount.
Western Blotting
Total protein lysate (50–65 µg) was run on a 4–12% NuPAGE Bis Tris gel (Invitrogen). 
Proteins were then transferred onto PVDF membrane using an iBlot system, and blocked in 
5% milk/TBST for 1 hour. All primary antibodies were diluted in 5% milk/TBST and 
incubated over night at 4°C. The membranes were washed in TBST and probed with the 
corresponding HRP-conjugated secondary antibody (0.2–0.02 µg/ml of anti-mouse, 
streptavidin, or anti-rabbit). Proteins were visualized using, ECL prime (Amersham, 
Uppsala, Sweden), or Luminata Crescendo (Millipore, Billerica, MA).
Lentiviral infection
All clones used are described in the Supplementary Information. All shRNA was obtained 
from the TRC shRNA library available through the Molecular Screening Facility at The 
Wistar Institute. Lentiviral production was carried out as described in the protocol developed 
by the TRC library (Broad Institute). Briefly, 293T cells were co-transfected with shRNA 
vector and lentiviral packaging plasmids (pCMV-dR8.74psPAX2, pMD2.G). The 
supernatant containing virus was harvested at 36 and 60 hours, combined and filtered 
through a 0.45µm filter. For transduction, the cells were layered overnight with lentivirus 
containing 8µg/ml polybrene. The cells were allowed to recover for 24 hours and then 
selected using 1µg/ml puromycin.
MTS Assays
Cells (1.5×103/well) were plated in a 96 well plate and treated with PLX4720. After 48 h, 
cells were incubated with MTS dye (20 µl/well) for 2 h. Absorbance was determined at 490 
nm using an EL800 microplate reader (BioTek, Winooski, VT). The percent cell 
proliferation was calculated by converting the experimental absorbance to percentage of 
control and plotted vs drug concentration. The values were then analyzed using a nonlinear 
dose-response analysis in GraphPad Prism.
Illumina oligonucleotide microarray
Transcriptional profiling was determined using Illumina Sentrix BeadChips. Total RNA was 
used to generate biotin-labeled cRNA using the Illumina TotalPrep RNA Amplification Kit. 
In short, 0.5 µg of total RNA was first converted into single-stranded cDNA with reverse 
transcriptase using an oligo-dT primer containing the T7 RNA polymerase promoter site and 
then copied to produce double-stranded cDNA molecules. The double stranded cDNA was 
cleaned and concentrated with the supplied columns and used in an overnight in-vitro 
transcription reaction where single-stranded RNA (cRNA) was generated incorporating 
biotin-16-UTP. A total of 0.75 µg of biotin-labeled cRNA was hybridized at 58°C for 16 h to 
Illumina's Sentrix Human HT-12 v3 Expression BeadChips (Illumina, San Diego, CA). Each 
BeadChip has around 48,000 transcripts with approximately 15-fold redundancy. The arrays 
were washed, blocked and the labeled cRNA was detected by staining with streptavidin-Cy3. 
Hybridized arrays were scanned using an Illumina BeadStation 500× Genetic Analysis 
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Systems scanner and the image data extracted using the Illumina GenomeStudio software, 
version 1.1.1). Data are available in the GEO database (accession # GSE57445).
Microarray analysis
Microarray expression data was quantile normalized and probes that showed low expression 
levels (detection p-value>0.05) across all samples were removed from the analysis. 
Expression values for each cell line were tested separately in multiple linear regression 
model with fibroblast age and experiment batches as predictor variables. Matlab v.8.0 
“regress” function was used to calculated p-values for each probe for association with 
fibroblast age. False Discovery Rate (FDR) was estimated using Benjamini-Hochberg 
procedure and only probes that showed FDR<5% in all 3 cell lines were considered 
significant. Heatmap was plotted using average expression values for 3 groups of age 
(young, middle and aged) normalized to aged group (100%).
In vivo Tail Vein Metastases Assay
All animal experiments were approved by the Institutional Animal Care and Use Committee 
(IACUC) (IACUC #112503Y_0) and were performed in an Association for the Assessment 
and Accreditation of Laboratory Animal Care (AAALAC) accredited facility. Male C57BL6 
mice 6–8 weeks (young) and 52 weeks of age (aged) were purchased from Taconic. YUMM 
1.7 (1×106 cells/100 µl PBS) or B16F10 (2.5×105/100 µl PBS) were injected into the tail 
vein of C57BL6 mice. Alternatively, Yumm1.7 cells were overexpressed with mCherry 
plasmid (pLU-EF1-MCS-mcherry) using lentivirus. The cells were sorted for mcherry and 
1×106 cells/100 µl PBS were injected into tail vein of young C57BL6 mice. After 4 weeks, 
the mice were euthanized, lungs were harvested and metastases counted. Lungs were fixed 
in paraffin and stained with H&E. Alternatively, lungs were harvested and imaged for 
presence of metastatic melanoma cells using Perkin-Elmer IVIS 200 whole body imager. For 
experiments requiring recombinant sFRP2, mouse recombinant sFRP2 (1169-FR-025/CF, 
R&D) was diluted in 50µl PBS and injected at a concentration of 200ng per mouse twice a 
week. The levels of sFRP2 were monitored by submandibular blood withdrawal every two 
weeks.
In vivo PLX4720 assay
All animal experiments were approved by the Institutional Animal Care and Use Committee 
(IACUC) (IACUC #112503X_0) and were performed in an Association for the Assessment 
and Accreditation of Laboratory Animal Care (AAALAC) accredited facility. YUMM1.7 
(2.5 × 105 cells) were suspended in Matrigel (500 µg/ml) and injected subcutaneously into 
young (6 week) and aged (52 week) C57/BL6 mice (Taconic). When resulting tumors 
reached 200 mm3, mice were fed either AIN-76A chow or AIN-76A chow containing 417 
mg/kg PLX4720. Tumor sizes were measured every 3–4 days using digital calipers, and 
tumor volumes were calculated using the following formula: volume = 0.5 × (length × 
width2). Time-to-event (survival) was determined by a 5-fold increase in baseline volume 
(~1000 mm3) and was limited by the development of skin necrosis. Upon the occurrence of 
necrosis, mice were euthanized. For subsequent experiments involving sFRP2 manipulation, 
Yumm1.7 cells overexpressing mCherry were used. 1×106 cells were suspended in PBS and 
subcutaneously injected into either 6-week-old or 52-week-old male C57/BL6 mice 
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(Taconic). For treatment with recombinant sFRP2, the mice were injected with recombinant 
protein (200ng/ml) through the tail vein every 2 days as described above. For the 
experiments performed with sFRP2 blocking antibody (clone 80.8.6, #MABC539, EMD 
Millipore), the mice were treated with 1mg/kg antibody (either sFRP2 or isotype control, 
Biolegend, #400264) once per week via tail vein injections.
Comet Assay
WM35 and FS5 melanoma cells were seeded in 12 well plates and treated with conditioned 
media for 48 hours. The cells were harvested in ice cold PBS. The comet assay was 
performed using CometSlides (Trevigen). Briefly, 75µl of a 2×105 cell suspension was 
mixed with 500µl 1% low melting point agarose. 50µl of cell/agarose mixture was dropped 
into the wells and allowed to solidify. Slides were incubated in lysis buffer (1.2M NaCl, 
100nM EDTA, 0.1% Sarkosyl, pH10.0) for 1h at 4°C. Slides were then electrophoresed at 
25V for 12 min in alkaline buffer (0.03M NaOH, 2mM EDTA, pH8.0). After fixation in 
70% ethanol, comets were visualized by staining with SYBR Green (Fisher). The extent of 
DNA damage was measured as the artificial Olive Moment using Cometscore software 
downloaded from http://www.tritekcorp.com.
ROS Activation Assay
5000 melanoma cells were seeded in a 96 well plate in triplicate. The cells were then treated 
with conditioned media from young and aged fibroblasts as well as DMEM as control. 
Hydrogen peroxide was added at 1mM as control. After 72 hours, reactive oxygen species 
were measured using Cell Meter™ Fluorimetric Intracellular Total ROS Activity Assay Kit 
(#22901, AAT Bioquest, CA) according to the manufacturer’s protocol. The plates were 
measured using the PerkinElmer EnVision Xcite Multilabel plate reader using the filters for 
Ex/Em=520/605 nm. Alternatively, samples were imaged using PerkinElmer Operetta and 
the fluorescent signal was quantified using Harmony 3.0 software. The cell number was 
determined by Hoescht staining (Hoechst 33342, Invitrogen) and used to normalize the total 
fluorescence obtained from ROS staining.
Topflash assay
Topflash vectors were obtained from Addgene (M51 Super 8× FOPFlash/TOPFlash mutant, 
#12457; M50 Super 8× TOPFlash, 12456). WM35 cells were plated to achieve 70% 
confluency in 6-well plates. Cells were co-transfected with pTK-RLuc (Green Renilla 
Luciferase) along with either Topflash or Fopflash vectors. After 5 hours of transfection, 
cells were treated as required. After 48h, cells were harvested and luciferase activity was 
measured using Dual-Luciferase® Reporter (DLR™) Assay System (Promega, E1910). The 
firefly luciferase signal from each well was normalized to its Renilla Luciferase signal. 
Topflash/fopflash signal was determined from each treatment and graphed using Graphpad/
Prism.
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Treatment with N-acetyl cysteine
N-Acetyl-L-cysteine (NAC) was obtained from Sigma (A9165) and dissolved in sterile 
dH2O (stock 1M). Cells were treated for 48h and analyzed. After optimization, 10mM final 
concentration was used for subsequent experiments.
Cell Fractionation
Melanoma cells were seeded into T25 flasks and incubated for 72 hours with 6.5ml 
conditioned fibroblast media prepared as described above. Cells were then washed in PBS, 
harvested with TrypLE Express and fractionated using the cellular fractionation kit (NE-
PER, Fisher) as per manufacturer’s protocol. Cell lysates were then separated on an SDS-
PAGE gel and visualized using standard Western blotting procedures.
ELISA
Nunc™ MaxiSorp™ ELISA plates (ebiosciences, CA) were coated with 50µl of 3µg/ml 
sFRP2 (#ab137560, abcam) overnight at 4°C. Plates were washed in PBS containing 0.1% 
Tween and blocked in ELISA diluent (00-4202-56, ebiosciences, CA) for 2 hours. Serum 
was diluted 1:100 before addition to the plates and incubated overnight at 4°C. Next day, the 
plates were washed in PBS containing 0.1% Tween20 and incubated with detection antibody 
(MAB6838, R&D systems, MN) for 1h at room temperature. Plates were washed and 
incubated with secondary antibody for 1h. After washing, 100µl TMB (00-4201-56, 
ebiosciences, CA) was added to the plates and incubated for 15 minutes. The reaction was 
stopped using 50µl of 2N H2SO4 and absorbance was measured at 450nm.
β–galactosidase staining
Fibroblasts were plated into 12-well dishes, incubated for 48 h, washed with PBS and fixed 
in 2% formaldehyde/0.2% glutaraldehyde. Cells were then incubated in staining solution 
(150mM NaCl, Sigma, St. Louis, MO), 2mM MgCl2 (Sigma), 5mM K3Fe(CN)6 (Millipore), 
5mM K4Fe(CN)6 (Millipore), 40mM Na2PO4 (Sigma) pH5.5, 20mg/ml X-gal (Applichem, 
Darmstadt, Germany) at 37°C overnight. Stain was removed and cells were stored in 70% 
glycerol before being imaged.
Quantitative PCR
All primers are listed in the Supplementary Information. Mouse tissue was snap frozen in 
liquid nitrogen immediately after harvesting. 10mg of the lung tissue was homogenized and 
RNA was extracted using Trizol (Invitrogen) and RNeasy Mini kit (Qiagen) as described 
previously. 1µg RNA was used to prepare cDNA using iscript DNA synthesis kit (#1708891, 
Bio-Rad, CA). cDNA was diluted 1:5 before use for further reactions. Each 20µl well 
reaction comprised of 10µl Power SYBR Green Master mix (4367659, Invitrogen), 1µl 
primer mix (Final concentration 0.5µM) and 1µl cDNA. Standard curves were generated for 
all primers and each set of primers were normalized to 18 Primer pair.
Statistical Analysis
For in vitro studies, a Student's t-test or Wilcoxon rank-sum test (Mann Whitney) was 
performed for two-group comparison. Estimate of variance was performed and parameters 
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for the t-test were adjusted accordingly using Welch’s correction. ANOVA or Kruskal-Wallis 
test with post-hoc Bonferroni's or Holm-Sidak’s adjusted p-values was used for multiple 
comparisons. For dose response analysis, Spearman’s correlation was calculated. For in vivo 
studies, the indicated sample size for each experiment was designed to have 80% power at a 
two-sided alpha of 0.05 to detect a difference of large effect size about 1.25 between two 
groups on a continuous measurement. The fold change in tumor volume at each time point 
after treatment relative to baseline was calculated and then the fold change in treatment 
group relative to age matched control group was used with a mixed-effect model to evaluate 
the treatment effect between age groups. Stata 12.0 (StatCorp LP, College Station, TX, 
USA) was used for data analysis for in vivo studies and human samples. For other 
experiments, Graphpad/Prism6 was used for plotting graphs and statistical analysis. 
Significance was designated as follows: *, p<0.05; **, p<0.01; ***, p<0.001. Extended 
statistical analyses for patient data are provided in the Supplementary Information.
Extended Data
Extended Data 1. Characterization of young and aged fibroblasts
Kaur et al. Page 12
Nature. Author manuscript; available in PMC 2016 October 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
1 × 106 Yumm1.7 cells were injected into the tail vein of young (8 weeks, n=10 mice) and 
aged (52 weeks, n=10 mice) mice, and 3 weeks later, lungs were assessed for metastatic 
colonies. Samples were analyzed by H&E staining. Number of mice with metastatic 
colonies in the lungs was quantified in graph (a). Proliferation rate of aged and young 
fibroblasts was measured by simple cell counts over a period of 12 days. Analysis of 
variance (ANOVA) is insignificant (p=0.234) (b). Young and aged fibroblasts were assessed 
for basal β-galactosidase activity after 5 passages in culture. Representative images from 2 
cell lines are shown for young and aged fibroblasts, magnification 100× (c). Staining of 
fibroblasts in skin reconstructs with α-SMA-1 to assess persistence of fibroblasts in cell 
culture. Representative images, magnification 150× (d). WM793 melanoma cells were 
grown in organotypic 3D skin reconstructs built with 3 different fibroblast cell lines derived 
from healthy young (25–35) and healthy aged (55–65) individuals. Representative images, 
magnification 150×. Invasion was quantified using NIS Element software. Analysis of 
variance (ANOVA) was performed (p=0.007). Holm-Sidak multiple comparisons comparing 
each young cell line with each aged cell line indicated p<0.05 (e). WM793 melanoma cells 
exposed to conditioned media from young and aged fibroblasts were assessed for 
proliferation using simple cell counts. Repeated measures analysis of variance (ANOVA) 
was calculated between samples (p=0.006). Bonferroni’s multiple comparisons test on day 7 
and 9 was performed to obtain adjusted p value [day 7 (p=0.047), day 9 (p=0.0004)] (f). 
Multiple melanoma cells were allowed to form spheroids followed by treatment with 
conditioned media from aged or young fibroblasts for 48h. The spheroids were then 
examined for their ability to invade in a collagen matrix (g). Data are represented as mean ± 
s.d. for each graph (b,e,f).
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Extended Data 2. sFRP2 promotes invasion and angiogenesis
Conditioned media from young fibroblasts treated with either control (PBS), or rsFRP2 
(200ng/ml) was used to pre-treat WM793 melanoma cells for 48h. Invasion was assayed 
using a Boyden Chamber assay over 24–72h. Two-tailed unpaired t test was performed 
(p=0.033) (a). Conditioned media from aged fibroblasts treated with sFRP2 blocking 
antibody (15µg/ml) for 72h was used to pre-treat WM793 melanoma cells for 48h. The 
invasion of melanoma cells was assessed in a Boyden Chamber assay for 24–72h. Two-
tailed unpaired t test was performed (p=0.035) (b). Young mice (8 weeks, 10 /group) were 
injected subcutaneously with Yumm1.7 cells. After palpable tumor appeared, mice were 
treated with rsFRP2 (200ng/mL) for 30 days and examined for angiogenesis using CD31 
staining. Representative images, magnification 400× (c,d). Aged mice (52 weeks, n= 5 /
group) were injected subcutaneously with Yumm1.7 cells and treated with either control 
IgG2aκ or sFRP2 blocking antibody (1mg/kg) for 3 weeks. Tumors were examined for 
angiogenesis by CD31 staining. Representative images, magnification 400× (e, f). Data are 
represented as mean ± s.d. for each graph (a,b).
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Extended Data 3. Treatment of aged tumor bearing mice with an α-sfrp2 antibody results in a 
lethal inflammation
Cytokine analysis of lungs in aged tumor-bearing mice (52 weeks, n=5 /group) treated with 
IgG2aκ or α-sFRP2 antibody (1mg/kg, once weekly for 3 weeks). RT-PCR demonstrates a 
difference in the lungs of mice treated with IgG2aκ or α-sFRP2 in cytokines CCL5 (a), IL4 
(b), IL10 (c), CXCL9 (d), IFNγ (e), and IL2 (f). Early response inflammatory genes TNFα 
(g) and IL6 (h) were no longer significantly altered. Estimate of variance was performed for 
all genes. For all cytokines, two-tailed unpaired t test was performed *=p<0.05, **=p<0.02. 
Data are represented as mean ± s.d. for each graph.
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Extended Data 4. β-catenin loss in the aged microenvironment
β-catenin expression in normal human skin from young and aged donors, with a focus on the 
fibroblast population (zoom) (a). β-catenin nuclear translocation in melanoma cells treated 
with conditioned media from aged as compared to young fibroblasts as measured by Western 
analysis (b) and a TOPFLASH assay. Two-tailed unpaired t test was performed to indicate 
statistical significance between treatment with young and aged media (p=0.023). Data are 
represented as mean ± s.d. (c). Immunofluorescent analysis of β-catenin in melanoma cells 
treated with media from young fibroblasts in which the β-catenin is knocked down (d).
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Extended Data 5. Increase in oxidative stress in the aged microenvironment
APE1 expression in normal human skin as measured by immunohistochemistry. Slides were 
scored for intensity of stain (3-highest, 0-lowest, <35yr, n=12; >55yr, n=7). Representative 
images, magnification 400× (left) and 200× (right). Unpaired t test using rank sum (Mann 
Whitney) revealed statistical significance (p=0.009) (a). Western analysis of SOD3 (b) and 
PRDX6 (c) levels in conditioned media from young and aged fibroblasts. 
Immunofluorescent analysis of 8-oxo-dG in normal young and aged skin stained for 
oxidative stress marker 8-oxo-dG (red), smooth muscle actin (green) and DAPI (blue) (d). 
ROS activity in melanoma cells with APE1 knockdown, after exposure to aged media. 
Analysis of variance was performed for each cell line treatment [FS13 (p=0.0006); FS14 
(p=0.004)]. For FS13, Two-tailed unpaired t test indicated significance (p<0.01) each 
shAPE1 cell line compared to control cells. For FS14, two-tailed unpaired t test indicated 
significance with p<0.05 each shAPE1 cell line compared to control cells (e). Data are 
represented as mean ± s.d. for each graph (a,e).
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Extended Data 6. Gene expression analysis of melanoma cells exposed to aged fibroblasts reveals 
increases in DNA damage
γH2AX expression was analyzed in melanoma cells exposed to H2O2 using 
immunofluorescence (a). Microarray analysis of the gene expression profiles of melanoma 
cells exposed to young/middle (Y/M) and aged fibroblasts identified 63 genes commonly 
increased in 3 melanoma cell lines cultured with aged vs young fibroblasts (b). 33 genes 
involved in DNA damage response were significantly altered due to effects of aging 
microenvironment in three different melanoma cell lines. Color scale indicates expression 
levels relative to aged group (c).
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Extended Data 7. DDR response is increased in melanoma cells exposed to aged fibroblasts
Skin reconstructs made with young or aged fibroblasts were stained with anti 53BP1 (a) or 
γH2AX (b) and analyzed by immunofluorescence. FS5 melanoma cell line treated with 
conditioned media from young and aged fibroblasts showing DNA damage as measured by a 
comet assay. Two-tailed unpaired t test with Welch’s correction was performed between 
young and aged treatments (p=0.039). Data are represented as mean ± s.e.m. (c). Percent 
ROS activity remaining after NAC treatment of aged fibroblasts. Spearman’s correlation 
between dose and percent inhibition is significant [p=0.043, r=−0.700] Data are represented 
as mean ± s.d. (d). Knockdown of SOD3 in young fibroblasts as analyzed by Western 
blotting (e). Young fibroblasts (2003,071-032 and AG11732) were treated with rsFRP2 
(200ng/ml) for 72h and this conditioned media was used to treat melanoma cells for 48h. 
Cells were assessed for DNA damage by γH2AX (f). Aged fibroblasts (AG13004 and 
AG11726) were treated with α-sFRP2 (15µg/ml) for 72h and this conditioned media was 
used to treat melanoma cells for 48h. Cells were assessed for DNA damage by γH2AX (g).
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Extended Data 8. Analysis of sFRP2, β-catenin, MITF, 8-oxo-dG, APE1, and 53BP1 in individual 
patients
Multiple melanoma samples from aged patients (red bars), and young patients (black bars) 
were compared. Bars represent average staining intensity (3- highest, 0-lowest) in all 
patients (n=9/group) for indicated proteins (a). Dot plots of staining intensity (0–3+) in 
individual patient samples for: sFRP2 (b) β-catenin (c) MITF (d) APE1 (e), 8-oxodG (f) and 
53BP1 (g). pvalues for each graph obtained by Mann Whitney tests.
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Extended Data 9. β-catenin predicts for sensitivity to vemurafenib
Melanoma spheroids were embedded in collagen and treated with 1µM PLX4720 in the 
presence of conditioned media from either young or aged fibroblasts. After 48h, spheroids 
were assessed for cell death by staining with ethidium homodimer (magnification, 40×) (a). 
In cells intrinsically sensitive to vemurafenib in culture, β-catenin expression is increased 
(b). Knockdown of β-catenin in Yumm1.7 cells decreases their sensitivity to PLX4720. 
Spearman’s correlation between dose and percent proliferation is significant in CTRL cells 
[p<0.0001, r=−1.000] whereas shCTNNB1 cells indicated no significant changes in curve 
after treatment [p=0.948, r=0.03] (c). Young mice (8 weeks, n=10 /group) were injected with 
rsFRP2 (200ng/mL, twice weekly) and skin was examined for β-catenin levels by 
immunohistochemistry. Representative images, magnification 200× (d). Yumm1.7 tumors 
were injected in aged mice pre-treated with α-sFRP2 antibody (1mg/kg, once weekly). Mice 
were then administered either control or 417mg/kg PLX4720 laced chow. Analysis of 
variance is significant between treatments (p<0.0001). Two-tailed unpaired t test using rank 
sum (Mann Whitney) was performed on tumor volumes on day 25 (1 week after treatment). 
Results were significant in sFRP2 treatment (p=0.036) and insignificant in IgG2aκ treatment 
(p=0.057) (e). Patient samples show a continuum of decreased response in relation to age, 
Spearman’s correlation between percent response and age is significant [r=0.243, p=0.035] 
(f). Data are represented as mean ± s.d for each graph (c,e).
Extended Data Table 1
Details Of Skin Fibroblasts Obtained From Healthy Donors.
Line Sex Age Disease State Tissue
Type
Biopsy Source
GM04390 F 23 Healthy Skin Arm
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Line Sex Age Disease State Tissue
Type
Biopsy Source
GM02674 F 29 Healthy Skin unspecified
AG11732 F 24 Healthy Skin Arm
AG07720 F 24 Healthy Skin Arm
AG11735 F 26 Healthy Skin Arm
AG07124 F 26 Healthy Skin Arm
TP-113 M 27 Healthy Skin Arm
2003-071-056 M 32 Healthy Skin Arm
GM02673 M 33 Healthy Skin unspecified
2003-071-051 M 23 Healthy Skin Arm
AG04062 M 31 Healthy Skin Arm
2003-071-032 M 28 Healthy Skin Arm
2003-071-057 M 31 Healthy Skin Arm
AG08620 F 64 Healthy Skin Arm
AG11726 F 56 Healthy Skin Arm
AG08517 F 66 Healthy Skin Arm
AG11489 F 66 Healthy Skin Arm
AG07757 F 61 Healthy Skin Arm
AG08529 F 60 Healthy Skin Arm
AG08701 F 62 Healthy Skin Arm
AG08379 F 60 Healthy Skin Arm
AG12597 F 62 Healthy Skin Arm
AG12988 F 56 Healthy Skin Arm
AG12589 F 68 Healthy Skin Arm
AG09878 F 61 Healthy Skin Arm
GM13335 M 57 Healthy Skin Arm
AG13095 M 62 Healthy Skin Arm
AG09157 M 63 Healthy Skin Arm
AG11079 M 63 Healthy Skin Arm
AG10942 M 50 Healthy Skin Arm
AG06281 M 67 Healthy Skin Arm
AG13004 M 68 Healthy Skin Arm
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The aged microenvironment promotes phenotype switching
Growth of 1×106 YUMM1.7_mCherry cells subcutaneously injected in young (8 weeks, 
n=10) and aged (52 weeks, n=10) C57/BL6 mice. (ANOVA p<0.0001; Multiple 
comparison’s test using Bonferroni correction, p<0.0001 after day 19)(a). CD31 expression 
from (a) (magnification 200×). Graph indicates percent of mice with extensive angiogenesis 
(multiple CD31+ vessels/ field) (b). mCherry staining in mouse lungs (positive cells circled 
in yellow; magnification 400×) (c). WM35 melanoma cells in skin reconstructs built with 
young or aged fibroblasts (n=3, magnification 150×). Invasion was quantified using ImageJ 
(ANOVA p=0.0006) (d). Ki67 staining from (d) (magnification 400×) (e). Proliferation of 
WM35 melanoma cells in conditioned media from young or aged fibroblasts (n=4 
fibroblasts/group) ANOVA, p=0.004; Holm Sidak correction [day 6 (p=0.002), day 8 
(p=0.034)] (f). Invasion of melanoma spheroids exposed to aged or young conditioned media 
(n=2 fibroblasts/group, magnification 40×, two-tailed unpaired t-test, p=0.041) (g). Boyden 
chamber invasion of FS5 melanoma cells treated with young vs. aged fibroblast media 
(magnification 150×, two-tailed unpaired t-test, p=0.043) (h). Data represented as mean±s.d. 
(a,d,g,h).
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Figure 2. sFRP2 promotes metastasis during aging
Western analysis of sFRP2 (media) and β-catenin (cell lysates) in fibroblasts (a). Invasion of 
melanoma spheroids (magnification 40×), treated with rsFRP2 (200ng/ml, 48h, two-tailed 
unpaired t-test, p=0.046) (b). Melanoma spheroids treated with media from aged fibroblasts 
pre-treated with either IgG2aκ, or α-sFRP2 monoclonal antibody (15µg/ml, 48h, 
magnification 40×, two-tailed unpaired t-test, p=0.023) (c). sFRP2 in mouse serum (n=10/
group): young, aged, and young + 200ng/mL rsFRP2. ANOVA (p=0.015), two-tailed 
unpaired t-test [PBS vs rsFRP2 (p=0.045), young vs aged mice (p=0.007)] (d). 1×106 
mCherry labeled Yumm 1.7 cells were injected intravenously into PBS or rsFRP2 
(200ng/mL) treated young mice (6–8 weeks, n=10/group). Graph indicates percent positive 
lungs recorded as IVIS fluorescence intensity where highest intensity is 3+(red), i.e., 
multiple metastatic foci, 0-lowest intensity, i.e., no metastases (green) (e). Yumm 1.7 tumors 
in young mice (6–8 weeks, n=10/group) treated with either PBS or rsFRP2 (200ng/mL) or in 
aged mice (52 weeks, n=5/group) treated with either control IgG2aκ, or α-sFRP2 
monoclonal antibody (1mg/kg) were assessed for CD31 (magnification 400×) (f). Western 
analysis of non-phosphorylated (active) β-catenin in melanoma cells treated with rsFRP2 for 
48h (g). β-catenin expression in young and aged human skin (<35yr, n=12; >55yr, n=7). 
Slides were scored for positivity (3-highest, 0-lowest), magnification 400×, unpaired t-test 
using rank-sum (p=0.019) (h). sFRP2 and β-catenin in Yumm1.7 tumors in young and aged 
mice (magnification 600×) (i). Aged tumor-bearing mice (>52 weeks, n=5/group) treated 
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with α-sFRP2 monoclonal antibody (1mg/kg). Tumors were stained for β-catenin 
(magnification 400×) (j). sFRP2 ELISA in shCTNNB1 vs. shCTRL fibroblast media. Two-
tailed unpaired t-test [2003-071-032 (p=0.015), TP113 (p=0.008)] (k). Invasion of 
melanoma spheroids treated with TP113 shCTNNB1 conditioned media for 48h 
(magnification 40×) (l). Data represented as mean±s.d. (b,c,d,h,k).
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Figure 3. Loss of APE1 renders melanoma cells more sensitive to oxidative stress in an aged 
microenvironment
β-catenin, APE1 and MITF in melanoma cells exposed to aged or young fibroblast media 
(a). APE1 in Yumm1.7 tumors in aged and young mice, percent positive tumors is quantified 
(magnification 400×) (b). ROS levels in multiple young and aged fibroblasts (two-tailed 
unpaired t-test, p=0.022) (c). Percent positive 8-oxo-dG Yumm1.7 tumors implanted in aged 
and young mice (magnification 400×) (d). Western analysis of WM35 melanoma cells after 
APE1 knockdown (e). ROS levels in shAPE1 melanoma cells in absence (two-tailed t-test, 
p=0.012), and presence (two-tailed t-test, p=0.008) of conditioned media from aged 
fibroblasts (f). 8-oxo-dG levels assessed in tumors from young mice treated with either PBS 
or rsFRP2 and aged mice treated with either IgG2aκ or α-sFRP2 (magnification 400×). (g). 
Schematic of sFRP2 effects in melanoma cells exposed to aged or young fibroblasts (h). 
Data represented as mean±s.d. (c,f).
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Figure 4. Melanoma cells in an aged microenvironment exhibit increased DNA damage markers
γH2AX and 53BP1 levels in Yumm1.7 tumors in aged and young mice (magnification 400×) 
(a), and in melanoma cells treated with conditioned media from young and aged fibroblasts 
(b). Comet assay analysis in melanoma cells treated with conditioned media from aged and 
young fibroblasts. Two-tailed unpaired t-test with Welch’s correction (young vs aged, 
p=0.002). Data represented as mean±s.e.m. (c). γH2AX in melanoma cells treated with 
conditioned media from aged fibroblasts pretreated with 20mM NAC (IF; 48h) (d), 
conditioned medium from young fibroblasts with SOD3 knock-down (IF; 72h) (e), or in 
melanoma cells with APE1 knockdown (Western; 48h) (f). γH2AX in melanoma cells 
exposed for 48h to conditioned media from young fibroblasts pre-treated with rsFRP2 or 
aged fibroblasts treated with α-sFRP2 antibody (72h) (g). 53BP1 in tumors from young mice 
treated with PBS or rsFRP2 and aged mice treated with IgG2aκ or α-sFRP2 (magnification 
600×) (h). Serum sFRP2 ELISA in young and aged melanoma patients (N=8 young, N=15 
aged; unpaired t-test with Welch’s correction, p=0.008). Data represented as mean±s.d. (i). 
Representative images from one young and aged patient for indicated proteins in the 
proposed pathway (magnification 400×) (j).
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Figure 5. The aged microenvironment induces therapy resistance
Yumm 1.7 tumors in young (8 weeks, n=10 mice/treatment) or aged (52 weeks, n=10 mice/
treatment) mice fed PLX4720 (417 mg/kg) chow. Tumors responded in young (p=6 ×10−5, 
two way paired t-test) (a), but not aged mice (p=0.361). Dotted lines indicate untreated 
controls (b). Melanoma spheroids were treated with 100nM H2O2 (48h), embedded in 
collagen and treated with young media containing 1µM PLX4720 (ANOVA, p<0.0001) (c). 
WM35 spheroids were embedded in collagen and treated with aged media containing 1µM 
PLX4720 and/or 20mM NAC. Invasion was measured after 48h (representative images, 
magnification 40×, one-way ANOVA, p=0.02). 20mM NAC (unpaired t-test, p=0.03) and 
1µM PLX4720 (two-tailed unpaired t-test, p=0.006) compared to control (d). Live-dead 
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staining of spheroids from (d). ANOVA, p<0.0001; Holm-Sidak’s multiple comparisons test 
indicated (p<0.0001) after pre-treatment with 20mM NAC in presence of either control or 
1µM PLX4720 (e). β-catenin staining of biopsies (magnification 200×) from patients 
undergoing vemurafenib treatment (percentage indicates percent RECIST response) (f). 
Tabulation of patient samples correlating H-score (intensity of stain per field of cells) to 
RECIST response (two-tailed paired t-test, p=0.035). 30% is considered a responder by 
RECIST criteria (g). Young mice (n=10/group) with Yumm1.7 tumors were treated with 
rsFRP2 (200ng/mL) bi-weekly. PLX4720 (417/mg/kg) was administered once the tumor 
reached 500mm3. rsFRP2-treated (red line) vs control (blue line) young mice (ANOVA, 
p=0.009; Holm-Sidak corrected multiple comparisons, p<0.05 after day 12, mean±s.e.m.) 
(h). Yumm1.7 tumors were injected in aged mice (52 weeks, n=5/group) pre-treated with α-
sFRP2 antibody (1mg/kg, once weekly). Mice were administered control or 417mg/kg 
PLX4720-laced chow. Tumor volume at day 25 is shown (unpaired t-test with Welch’s 
correction, p=0.048). (i). RECIST response in patients under 65 vs. over 65. Two sample 
Wilcoxon rank-sum (Mann Whitney) test indicated statistical significance (p=0.016) (j). 
Data represented as mean±s.d. (a,b,c,e,i,j).
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